...
首页> 外文期刊>Neuroscience: An International Journal under the Editorial Direction of IBRO >The purinergic P2 receptor antagonist pyridoxalphosphate-6-azophenyl-2'4'-disulphonic acid prevents both the acute locomotor effects of amphetamine and the behavioural sensitization caused by repeated amphetamine injections in rats.
【24h】

The purinergic P2 receptor antagonist pyridoxalphosphate-6-azophenyl-2'4'-disulphonic acid prevents both the acute locomotor effects of amphetamine and the behavioural sensitization caused by repeated amphetamine injections in rats.

机译:嘌呤能级P2受体拮抗剂吡ido醛磷酸盐-6-偶氮苯基-2'4'-二磺酸既可预防苯丙胺的急性运动作用,又可防止因反复注射苯丙胺而引起的大鼠行为敏化。

获取原文
获取原文并翻译 | 示例

摘要

Repeated administration of amphetamine-like psychostimulants produce a progressive and long-lasting hypersensitivity to their behavioural effects known as behavioural sensitization. Previous studies have shown that administration of the purinergic P2 receptor agonist 2-methylthio ATP into the nucleus accumbens of rats raises the extracellular level of dopamine accompanied with enhanced locomotion in a similar manner. Furthermore, the quantitative EEG after application of 2-methylthio ATP or amphetamine was characterized by an elevation of the alpha1-power. However, purinergic P2 receptor antagonists decreased the basal level of dopamine in the NAc and in addition prevented the effects of 2-methylthio ATP. The purpose of the present study was to investigate, whether endogenous ATP acting via purinergic P2 receptors is involved in the process of amphetamine-induced sensitization. Rats were treated systemically for five successive days with d-amphetamine (1.5 mg/kg) and tested in an open field with respect to their locomotor response. The enhanced locomotor activity after the first injection of amphetamine was diminished by the previous intracerebroventricular application of the purinergic P2 receptor antagonist pyridoxalphosphate-6-azophenyl-2'4'-disulphonic acid (PPADS; 0.6 nmol) (P<0.05). The challenge with a lower dose of amphetamine (0.75 mg/kg) produced an increased locomotion in comparison to the response after the first amphetamine application indicating the expression of a behavioural sensitization. Pretreatment with PPADS prior to each amphetamine administration prevented the increase of locomotor activity after the challenge with amphetamine (P<0.05). In summary, the present study demonstrates that PPADS blocks both the acute locomotor effects of amphetamine and the development of behavioural sensitization to the psychostimulant. We suggest that the activation of purinergic P2 receptors by endogenous ATP is necessary for the expression of these effects.
机译:反复服用苯丙胺样精神刺激药会对其行为效应(称为行为敏化)产生进行性和持久性超敏反应。先前的研究表明,将嘌呤能P2受体激动剂2-甲硫基ATP施用到大鼠伏隔核中,可以类似的方式提高多巴胺的细胞外水平,并增强运动能力。此外,应用2-甲硫基ATP或安非他明后的定量脑电图的特征在于α1能力的提高。然而,嘌呤能P2受体拮抗剂降低了NAc中多巴胺的基础水平,此外还阻止了2-甲硫基ATP的作用。本研究的目的是调查通过嘌呤能P2受体起作用的内源性ATP是否参与苯丙胺诱导的致敏过程。用d-苯异丙胺(1.5 mg / kg)对大鼠进行连续五天的全身性治疗,并在开阔的田野中测试其运动反应。首次在脑室内应用嘌呤能P2受体拮抗剂吡ido醛磷酸盐-6-偶氮苯基-2'4'-二磺酸(PPADS; 0.6 nmol)可以减少首次注射苯丙胺后运动能力的增强(P <0.05)。与第一次安非他明应用后的反应表明行为敏化的表达相比,用较低剂量的安非他明(0.75 mg / kg)进行的刺激产生的运动增加。每次给予苯丙胺之前用PPADS进行预处理可防止苯丙胺攻击后运动活动的增加(P <0.05)。总而言之,本研究表明,PPADS既能阻止苯丙胺的急性运动作用,又能阻止对精神兴奋剂的行为敏化。我们建议内源性ATP激活嘌呤能P2受体对于表达这些作用是必要的。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号